Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06475066 | Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging(COMBO-I) | not yet recruiting | N/A | 320 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06470633 | To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 29 | The First Affiliated Hospital with Nanjing Medical University |
| 0 |
| Jun 24, 2024 |
| clinicaltrials |
| NCT06422949 | Efficacy and Safety of HILOTERM® Device for the Prevention of Peripheral Neuropathy | not yet recruiting | N/A | 120 | European Institute of OncologyOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06424054 | Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects(eChemoCoach) | not yet recruiting | N/A | 746 | Noordwest ZiekenhuisgroepOTHER | 0 | May 21, 2024 | clinicaltrials |
| NCT06407310 | Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 25 | Tel Aviv Medical CenterOTHER | 0 | May 9, 2024 | clinicaltrials |
| NCT06404736 | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer(QUEEN-Dream) | not yet recruiting | Phase 2 | 73 | Fudan UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06383663 | Supraclavicular Lymph Node Dissection for Ipsilateral Supraclavicular Lymph Node Metastatic Breast Cancer | not yet recruiting | N/A | 452 | Sun Yat-sen UniversityOTHER | 0 | Apr 30, 2024 | clinicaltrials |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | not yet recruiting | Phase 2 | 68 | Li HuipingOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06371807 | Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab(KEYPARTNER) | not yet recruiting | Phase 2 | 20 | Fundacao ChampalimaudOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06354114 | A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011 | not yet recruiting | Phase 2 | 80 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT05986071 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers(MATRIX) | not yet recruiting | Phase 1 / Phase 2 | 57 | Institut Paoli-CalmettesOTHER | 1 | Mar 29, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05370300 | SNAPS Breast Cancer Patient Study Breast Cancer Patients | not yet recruiting | — | 500 | Immunis.AIINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06195371 | Impact of CASP3 Gene in Chemoresistance | not yet recruiting | — | 60 | Gehad Salah El-Din shakerOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06270355 | Stockholm Mammography Risk Stratified Trial(SMART) | not yet recruiting | Phase 3 | 70,000 | Karolinska InstitutetOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06268327 | Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy | not yet recruiting | Phase 2 / Phase 3 | 30 | Assiut UniversityOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT06245824 | Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial | not yet recruiting | Phase 4 | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06229067 | Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 182 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT06131632 | Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy(ConSIBreC) | not yet recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05993559 | Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy | not yet recruiting | Phase 3 | 1,314 | Gangnam Severance HospitalOTHER | 0 | Jan 12, 2024 | clinicaltrials |
| NCT06202313 | Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 128 | Shengjing HospitalOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT06193122 | Three-Dimensional Ultrasound and Spectroscopy as Early Indicators of Breast Cancer Response to Neoadjuvant Treatment | not yet recruiting | — | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06193707 | Intelligent Remote Intervention for High-risk Breast Cancer Populations | not yet recruiting | N/A | 1,250 | Qianfoshan HospitalOTHER | 0 | Jan 5, 2024 | clinicaltrials |
| NCT06175078 | Three-Dimensional Ultrasound Imaging and Spectroscopy for Characterizing Breast Masses | not yet recruiting | — | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT06154590 | Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor(NASBP-B-09) | not yet recruiting | — | 100 | DR. DIANE CHISESI NFS. MD. PHD.OTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT06110845 | CLinical Evaluation Of a comPuter Algorithm To Report BreAst cAncers (CLEOPATRAA)(CLEOPATRAA) | not yet recruiting | — | 800 | The Leeds Teaching Hospitals NHS TrustOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT06076772 | Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients | not yet recruiting | — | 54 | Assiut UniversityOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT05860907 | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis | not yet recruiting | Phase 4 | 384 | Fudan UniversityOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT06015113 | Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis | not yet recruiting | N/A | 20 | Xi'an International Medical Center HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05983094 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | not yet recruiting | Phase 2 | 181 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05980208 | A Real-world Study of Inetetamab for First-line Treatment of MBC | not yet recruiting | — | 150 | Hunan Cancer HospitalOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT05979220 | Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy | not yet recruiting | Phase 2 | 178 | Shuangyue LiuOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05901025 | Homologous Recombination Repair Pathway Gene Mutation Spectrum in Chinese Breast Cancer Patients | not yet recruiting | — | 5,000 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05613504 | Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. | not yet recruiting | N/A | 90 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05519670 | A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr(CAPRICE) | not yet recruiting | Phase 1 / Phase 2 | 72 | Institut Paoli-CalmettesOTHER | 0 | Aug 29, 2022 | clinicaltrials |
| NCT05505812 | Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | not yet recruiting | Early Phase 1 | 10 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05460819 | Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. | not yet recruiting | N/A | 90 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Jul 20, 2022 | clinicaltrials |
| NCT05285332 | Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy(CS) | not yet recruiting | N/A | 362 | Changhai HospitalOTHER | 0 | Jul 19, 2022 | clinicaltrials |
| NCT05452083 | Postoperative Radiation of Patients With Breast Cancer in Extreme Hypofractionation. | not yet recruiting | — | 100 | University of Erlangen-Nürnberg Medical SchoolOTHER | 0 | Jul 11, 2022 | clinicaltrials |
| NCT05431504 | The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis | not yet recruiting | Phase 2 | 53 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)(PHARE-C) | not yet recruiting | Phase 3 | 800 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT05287308 | Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study | not yet recruiting | N/A | 500 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05253170 | Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients | not yet recruiting | Phase 3 | 622 | Seoul National University Bundang HospitalOTHER | 0 | Mar 11, 2022 | clinicaltrials |
| NCT04929548 | Exploratory Study of Neoadjuvant Treatment of HER2-positive Breast Cancer With Py in Combination With HP | not yet recruiting | Phase 4 | 20 | Wuhan UniversityOTHER | 0 | Jan 5, 2022 | clinicaltrials |
| NCT05131893 | Neoadjuvant Treatment of Breast Cancer | not yet recruiting | — | 300 | National Institute of Oncology, HungaryOTHER | 1 | Nov 23, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2024source: clinicaltrials